TNF Pharmaceuticals Inc

FRA:DQS0 (USA)   Ordinary Shares
€ 1.89 (0%) Dec 27
At Loss
P/B:
0.19
Market Cap:
€ 3.30M ($ 3.45M)
Enterprise V:
€ -6.48M ($ -6.76M)
Volume:
-
Avg Vol (2M):
-
Trade In:

Business Description

TNF Pharmaceuticals Inc
NAICS : 541713 SIC : 2833
ISIN : US62856X1028

Share Class Description:

FRA:DQS0: Ordinary Shares
Description
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
Name Current Vs Industry Vs History
Cash-To-Debt 591.22
Equity-to-Asset 0.71
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -16.6
3-Year EPS without NRI Growth Rate -19.4
3-Year FCF Growth Rate -30.7
Name Current Vs Industry Vs History
14-Day RSI 26.47
12-1 Month Momentum % -65

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.72
Quick Ratio 1.72
Cash Ratio 1.52

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -17.7
Shareholder Yield % 2.49
Name Current Vs Industry Vs History
ROE % -209.15
ROA % -113.08
ROIC % -86.25
ROC (Joel Greenblatt) % -26223.5
ROCE % -73.73

Financials (Next Earnings Date:2025-02-14 Est.)

FRA:DQS0's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

TNF Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -12.744
Beta 2.11
Volatility % 55.89
14-Day RSI 26.47
14-Day ATR (€) 0.000007
20-Day SMA (€) 1.89
12-1 Month Momentum % -65
52-Week Range (€) 1.89 - 5.52
Shares Outstanding (Mil) 2.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

TNF Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

TNF Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

TNF Pharmaceuticals Inc Frequently Asked Questions

What is TNF Pharmaceuticals Inc(FRA:DQS0)'s stock price today?
The current price of FRA:DQS0 is €1.89. The 52 week high of FRA:DQS0 is €5.52 and 52 week low is €1.89.
When is next earnings date of TNF Pharmaceuticals Inc(FRA:DQS0)?
The next earnings date of TNF Pharmaceuticals Inc(FRA:DQS0) is 2025-02-14 Est..
Does TNF Pharmaceuticals Inc(FRA:DQS0) pay dividends? If so, how much?
TNF Pharmaceuticals Inc(FRA:DQS0) does not pay dividend.

Press Release

Subject Date
No Press Release